16th Swiss Course on Medicinal Chemistry 2026
Leysin, Switzerland
4.-9. October 2026, Alpine Classic Hotel
16th Swiss Coursee on Medicinal Chemistry 2026
Leysin, Switzerland
Leysin, Switzerland
4.-9. October 2026, Alpine Classic Hotel
Program
16.00
Course check in
18.00
Welcome and Conference Opening Dinner
20.00
Welcome and Introduction into program and tutorials by Gerhard Müller
20.15
Gerhard Müller, SpiroChem
«Personal reflections on this week’s program»
08.00
Mattew LaMarche, Sanofi
09.00
Andreas Goutopoulos, Actithera
10.00
Coffee Break
10.30
Annelli Nordqvist, AstraZeneca
«AZD2389, a first in class small molecule inhibitor of fibroblast activation protein (FAP)»
11.30
Uwe Grether, Roche
12.30
Lunch
14.00
Anna Hirsch, Universität des Saarland
15.15
J. Veerman, ZoBio / M. Carneiro, ZoBio
«Discovery and Optimization of Bromodomain Inhibitors»
K. Ritter, University of Tübingen
«tba.»
M. Whittaker, Ebryl Ltd. / M. Mazanetz, Ebryl Ltd.
«Fragment – Based Lead Generation»
J. Viklund, AstraZeneca
«Fragment and Structure – Based Drug Design»
17.45
Coffee Break
18.00
Maria Duca, Université Côte d'Azur
«Targeting Non-coding RNAs Using Synthetic Small Molecules»
19.00
Tilly Bingham, Cumulus Oncology
«GPCRs, the Druggable Target Class "Gift That Keeps on Giving"!»
20.00
Dinner
08.00
Zoran Rankovic, ICR The Institute for Cancer Research Centre for Protein Degradation
09.00
Zuzanna Kozicka, EPFL Lausanne
«Molecular glue degraders: fantastic drugs and where to find them»
10.00
Coffee Break
10.30
Adrian Whitty, Boston University
«Macrocycles and Other «Beyond Rule-of-Five» Chemotypes»
11.30
Gerhard Müller, Spirochem
«New targets, modalities»
12.30
Lunch
14.00
Peter Tonge, Stony Brook University
«Kinetic Selectivity – A Missed Opportunity in Drug Discovery?»
15.15
J. Veerman, ZoBio / M. Carneiro, ZoBio
«Discovery and Optimization of Bromodomain Inhibitors»
K. Ritter, University of Tübingen
«tba.»
M. Whittaker, Ebryl Ltd. / M. Mazanetz, Ebryl Ltd.
«Fragment – Based Lead Generation»
J. Viklund, AstraZeneca
«Fragment and Structure – Based Drug Design»
08.00
Jean-Louis Reymond, University of Bern
«Artificial intelligence in early-phase drug discovery»
09.00
Pat Walters, OpenADMET
10.00
Coffee Break
10.30
Edmund Hoppe, Boehringer-Ingelheim
«Relevance and Application of ADME and PK Data 1»
11.30
Edmund Hoppe, Boehringer-Ingelheim
«Relevance and Application of ADME and PK Data 2»
12.30
Lunch
14.00
Mark Murcko, Relay Therapeutics
08.00
Beat Ernst, University of Basel
09.00
Andrew Mortlock, Astellas Pharma
10.00
Coffee Break
10.30
Chun-wa Chung, GSK R&D
«The Application of Biophysical Methods in Drug Discovery»
11.30
Stephan Theisgen, Senior Scientist, ZoBio
«NMR in Drug Discovery - an Underestimated Biophysics Area»
12.30
Lunch
14.30
J. Veerman, ZoBio / M. Carneiro, ZoBio
«Discovery and Optimization of Bromodomain Inhibitors»
K. Ritter, University of Tübingen
«tba.»
M. Whittaker, Ebryl Ltd. / M. Mazanetz, Ebryl Ltd.
«Fragment – Based Lead Generation»
J. Viklund, AstraZeneca
«Fragment and Structure – Based Drug Design»
17.00
Coffee Break
17.30
Thomas Harth, Ysios Capital
09.00
Henrick Möbitz, Novartis
«Discovery of HRO761, a novel, first-in-class clinical stage WRN inhibitor by structure and property-based design using ab initio conformational analysis»
10.00
Stefan Laufer, University of Tübingen
11.00
Nicholas Meanwell, Distinguished Professor, The Baruch S. Blumberg Institute, Doylestown, PA Adjunct Professor, Department of Medicinal Chemistry, School of Pharmacy, U. Michigan, Ann Arbor, MI Adjunct Professor, Ernest Mario School of Pharmacy, Rutgers University, New Brunswick, NJ Principal, NuArq MedChem Consulting LLC
12.00
Gerhard Müller, SpiroChem
concluding remarks
12.15
Lunch and End of the course